{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:08:37Z","timestamp":1788304117330,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171101"],"award-info":[{"award-number":["82171101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["7242019"],"award-info":[{"award-number":["7242019"]}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2024-2-1082"],"award-info":[{"award-number":["2024-2-1082"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["H020420160130"],"award-info":[{"award-number":["H020420160130"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes","award":["PWD&RPP-MRI, JYY2023-6"],"award-info":[{"award-number":["PWD&RPP-MRI, JYY2023-6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90074-4","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T02:24:16Z","timestamp":1739845456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical observation of esculin and digitalisglycosides eye drops with 0.3% sodium hyaluronate eye drops for dry eye disease: a randomized controlled trial"],"prefix":"10.1038","volume":"15","clinical-trial-number":[{"clinical-trial-number":"chictr2400093427","registry":"10.18810\/chictr"}],"author":[{"given":"Yinghui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"90074_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton, F. et al. TFOS DEWS II epidemiology report. Ocul Surf. 15, 334\u2013365. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.003 (2017).","journal-title":"Ocul Surf."},{"key":"90074_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jtos.2020.04.003","volume":"18","author":"MTM Wang","year":"2020","unstructured":"Wang, M. T. M. et al. Systemic risk factors of dry eye disease subtypes: A New Zealand cross-sectional study. Ocul Surf. 18, 374\u2013380. https:\/\/doi.org\/10.1016\/j.jtos.2020.04.003 (2020).","journal-title":"Ocul Surf."},{"key":"90074_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn, J. S. et al. TFOS DEWS II Diagnostic methodology report. Ocul Surf. 15, 539\u2013574. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.001 (2017).","journal-title":"Ocul Surf."},{"key":"90074_CR4","doi-asserted-by":"publisher","unstructured":"Kojima, T., Dogru, M., Kawashima, M., Nakamura, S. & Tsubota, K. Advances in the diagnosis and treatment of dry eye. Prog. Retin Eye Res. 100842. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100842 (2020).","DOI":"10.1016\/j.preteyeres.2020.100842"},{"key":"90074_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones, L. et al. TFOS DEWS II management and therapy report. Ocul Surf. 15, 575\u2013628. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.006 (2017).","journal-title":"Ocul Surf."},{"key":"90074_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/02713683.2020.1849733","volume":"46","author":"S Belalcazar-Rey","year":"2021","unstructured":"Belalcazar-Rey, S. et al. Efficacy and safety of sodium hyaluronate\/chondroitin sulfate preservative-free ophthalmic solution in the treatment of dry eye: A clinical trial. Curr. Eye Res. 46, 919\u2013929. https:\/\/doi.org\/10.1080\/02713683.2020.1849733 (2021).","journal-title":"Curr. Eye Res."},{"key":"90074_CR7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1080\/02713683.2017.1297462","volume":"42","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Comparison of 0.3% hypotonic and isotonic sodium hyaluronate eye drops in the treatment of experimental dry eye. Curr. Eye Res. 42, 1108\u20131114. https:\/\/doi.org\/10.1080\/02713683.2017.1297462 (2017).","journal-title":"Curr. Eye Res."},{"key":"90074_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1089\/jop.2018.0032","volume":"34","author":"IC You","year":"2018","unstructured":"You, I. C. et al. Comparison of 0.1%, 0.18%, and 0.3% hyaluronic acid eye drops in the treatment of experimental dry eye. J. Ocul Pharmacol. Ther. 34, 557\u2013564. https:\/\/doi.org\/10.1089\/jop.2018.0032 (2018).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"90074_CR9","doi-asserted-by":"publisher","first-page":"1675957","DOI":"10.1155\/2020\/1675957","volume":"2020","author":"EHM Hassanein","year":"2018","unstructured":"Hassanein, E. H. M., Sayed, A. M., Hussein, O. E. & Mahmoud, A. M. Coumarins as modulators of the Keap1\/Nrf2\/ARE signaling pathway. Oxid. Med. Cell. Longev. 2020, 1675957. https:\/\/doi.org\/10.1155\/2020\/1675957 (2020).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"90074_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ja.2014.127","volume":"68","author":"I Mokdad-Bzeouich","year":"2015","unstructured":"Mokdad-Bzeouich, I. et al. Oligomerization of esculin improves its antibacterial activity and modulates antibiotic resistance. J. Antibiot. (Tokyo) 68, 148\u2013152. https:\/\/doi.org\/10.1038\/ja.2014.127 (2015).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"90074_CR11","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1021\/jf403840c","volume":"62","author":"KS Kang","year":"2014","unstructured":"Kang, K. S. et al. Protective effect of esculin on streptozotocin-induced diabetic renal damage in mice. J. Agric. Food Chem. 62, 2069\u20132076. https:\/\/doi.org\/10.1021\/jf403840c (2014).","journal-title":"J. Agric. Food Chem."},{"key":"90074_CR12","doi-asserted-by":"publisher","first-page":"110177","DOI":"10.1016\/j.intimp.2023.110177","volume":"119","author":"J Ni","year":"2023","unstructured":"Ni, J. et al. Esculin alleviates LPS-induced acute lung injury via inhibiting neutrophil recruitment and migration. Int. Immunopharmacol. 119, 110177. https:\/\/doi.org\/10.1016\/j.intimp.2023.110177 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"90074_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1513\/AnnalsATS.201608-649OC","volume":"14","author":"PL Zeitlin","year":"2017","unstructured":"Zeitlin, P. L. et al. Digitoxin for airway inflammation in cystic fibrosis: Preliminary assessment of safety, pharmacokinetics, and dose finding. Ann. Am. Thorac. Soc. 14, 220\u2013229. https:\/\/doi.org\/10.1513\/AnnalsATS.201608-649OC (2017).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"90074_CR14","first-page":"1099","volume":"46","author":"ZY Jiang","year":"2010","unstructured":"Jiang, Z. Y. et al. The clinical efficacy and safety study of esculin and digitalis glycosides eye drops in treating ametropic asthenopia. Zhonghua Yan Ke Za Zhi 46, 1099\u20131103 (2010).","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"90074_CR15","doi-asserted-by":"publisher","first-page":"e681","DOI":"10.1111\/aos.14961","volume":"100","author":"F Lin","year":"2022","unstructured":"Lin, F., Mao, X., Ma, L. & Liu, H. An investigation into the effects of ocular nebulization combined with meibomian gland massage on ocular surface status and corneal higher-order aberrations for the treatment of meibomian gland dysfunction. Acta Ophthalmol. 100, e681\u2013e693. https:\/\/doi.org\/10.1111\/aos.14961 (2022).","journal-title":"Acta Ophthalmol."},{"key":"90074_CR16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.13703\/j.0255-2930.20221009-0001","volume":"43","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. [Combination of acupuncture and medication for dry eye complicated with computer vision syndrome: a randomized controlled trial]. Zhongguo Zhen Jiu. 43, 1134\u20131138. https:\/\/doi.org\/10.13703\/j.0255-2930.20221009-0001 (2023).","journal-title":"Zhongguo Zhen Jiu"},{"key":"90074_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","volume":"128","author":"KL Miller","year":"2010","unstructured":"Miller, K. L. et al. Minimal clinically important difference for the ocular surface disease index. Arch. Ophthalmol. 128, 94\u2013101. https:\/\/doi.org\/10.1001\/archophthalmol.2009.356 (2010).","journal-title":"Arch. Ophthalmol."},{"key":"90074_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtos.2019.01.004","volume":"17","author":"C Begley","year":"2019","unstructured":"Begley, C. et al. Review and analysis of grading scales for ocular surface staining. Ocul Surf. 17, 208\u2013220. https:\/\/doi.org\/10.1016\/j.jtos.2019.01.004 (2019).","journal-title":"Ocul Surf."},{"key":"90074_CR19","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1080\/09273948.2022.2094812","volume":"31","author":"M Gao","year":"2023","unstructured":"Gao, M. et al. Evaluation of the efficacy and safety of topical 0.05% cyclosporine eye drops (II) in the treatment of dry eye associated with primary Sjogren\u2019s syndrome. Ocul Immunol. Inflamm. 31, 1662\u20131668. https:\/\/doi.org\/10.1080\/09273948.2022.2094812 (2023).","journal-title":"Ocul Immunol. Inflamm."},{"key":"90074_CR20","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1007\/s13277-015-4209-1","volume":"37","author":"I Mokdad-Bzeouich","year":"2016","unstructured":"Mokdad-Bzeouich, I. et al. Esculin and its oligomer fractions inhibit adhesion and migration of U87 glioblastoma cells and in vitro angiogenesis. Tumour Biol. 37, 3657\u20133664. https:\/\/doi.org\/10.1007\/s13277-015-4209-1 (2016).","journal-title":"Tumour Biol."},{"key":"90074_CR21","doi-asserted-by":"publisher","first-page":"117787","DOI":"10.1016\/j.lfs.2020.117787","volume":"254","author":"RS Serralha","year":"2020","unstructured":"Serralha, R. S. et al. Esculin reduces P2X7 and reverses mitochondrial dysfunction in the renal cortex of diabetic rats. Life Sci. 254, 117787. https:\/\/doi.org\/10.1016\/j.lfs.2020.117787 (2020).","journal-title":"Life Sci."},{"key":"90074_CR22","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jad.2020.08.065","volume":"277","author":"T Chen","year":"2020","unstructured":"Chen, T., Zheng, M., Li, Y., Liu, S. & He, L. The role of CCR5 in the protective effect of Esculin on lipopolysaccharide-induced depressive symptom in mice. J. Affect. Disord. 277, 755\u2013764. https:\/\/doi.org\/10.1016\/j.jad.2020.08.065 (2020).","journal-title":"J. Affect. Disord."},{"key":"90074_CR23","doi-asserted-by":"publisher","first-page":"265798","DOI":"10.1155\/2015\/265798","volume":"2015","author":"JA Leite","year":"2015","unstructured":"Leite, J. A. et al. Ouabain modulates zymosan-induced peritonitis in mice. Mediat. Inflamm. 2015, 265798. https:\/\/doi.org\/10.1155\/2015\/265798 (2015).","journal-title":"Mediat. Inflamm."},{"key":"90074_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12974-014-0218-z","volume":"11","author":"PF Kinoshita","year":"2014","unstructured":"Kinoshita, P. F. et al. Signaling function of Na,K-ATPase induced by ouabain against LPS as an inflammation model in hippocampus. J. Neuroinflammation. 11, 218. https:\/\/doi.org\/10.1186\/s12974-014-0218-z (2014).","journal-title":"J. Neuroinflammation"},{"key":"90074_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.intimp.2015.03.017","volume":"26","author":"J Lee","year":"2015","unstructured":"Lee, J. et al. Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation. Int. Immunopharmacol. 26, 103\u2013111. https:\/\/doi.org\/10.1016\/j.intimp.2015.03.017 (2015).","journal-title":"Int. Immunopharmacol."},{"key":"90074_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nature09978","volume":"472","author":"JR Huh","year":"2011","unstructured":"Huh, J. R. et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR\u03b3t activity. Nature 472, 486\u2013490. https:\/\/doi.org\/10.1038\/nature09978 (2011).","journal-title":"Nature"},{"key":"90074_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron, A. J. et al. TFOS DEWS II pathophysiology report. Ocul Surf. 15, 438\u2013510. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.011 (2017).","journal-title":"Ocul Surf."},{"key":"90074_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/archopht.124.5.710","volume":"124","author":"A Gulati","year":"2006","unstructured":"Gulati, A., Sacchetti, M., Bonini, S. & Dana, R. Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. Arch. Ophthalmol. 124, 710\u2013716. https:\/\/doi.org\/10.1001\/archopht.124.5.710 (2006).","journal-title":"Arch. Ophthalmol."},{"key":"90074_CR29","doi-asserted-by":"publisher","first-page":"C1305","DOI":"10.1152\/ajpcell.00086.2020","volume":"318","author":"DG Puro","year":"2020","unstructured":"Puro, D. G. How goblet cells respond to dry eye: Adaptive and pathological roles of voltage-gated calcium channels and P2X(7) purinoceptors. Am. J. Physiol. Cell. Physiol. 318, C1305\u2013c1315. https:\/\/doi.org\/10.1152\/ajpcell.00086.2020 (2020).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"90074_CR30","first-page":"744","volume":"14","author":"F Taylor","year":"1985","unstructured":"Taylor, F. Drugs affecting the eye. Aust. Fam. Phys. 14, 744\u2013745 (1985).","journal-title":"Aust. Fam. Phys."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90074-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T02:24:25Z","timestamp":1739845465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90074-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90074"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90074-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research was conducted in compliance with the Declaration of Helsinki, the Good Clinical Practices Standards. It was approved by the Medical Ethics Committee of Beijing Tongren Hospital, Capital Medical University (ethics number: TREC2022-118) and was registered with the Chinese Clinical Trial Registry in 30\/05\/2023 (ChiCTR2300071953). Before the study began, informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"5747"}}